NMT Medical Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter 2009 total revenues were approximately $3.0 million compared with approximately $4.2 million for the quarter ended September 30, 2008. For the third quarter of 2009, the company narrowed its net loss to approximately $2.9 million, or $0.22 per share, compared with a net loss of approximately $4.4 million, or $0.33 per share, for the corresponding period in 2008. Total revenues were down approximately 28% year-over-year. Loss from operations was $2.9 million and loss before income taxes was $2.8 million against loss from operations was $4.4 million and loss before income taxes was $4.3 million for the same period a year ago. Total revenues for the nine months ended September 30, 2009 were approximately $9.7 million compared with approximately $13.4 million for the same period in 2008. The net loss for the nine months ended September 30, 2009 was reduced to approximately $10.5 million, or $0.80 per share, compared with a net loss of approximately $13.9 million, or $1.07 per share, for the corresponding period in 2008. Loss from operations was $10.6 million and loss before income taxes was $10.5 million against loss from operations was $14.4 million and loss before income taxes was $13.8 million for the same period a year ago. The company currently is expecting total revenues of $13 to $14 million for the full year 2009.

NMT Medical Inc., Q3 2009 Earnings Call, Oct 29 2009

NMT Medical Inc. announced that it will commence data analysis for its landmark patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) clinical trial--originally scheduled for the fall of 2010--in April 2010. At that time, 99.4% of all patient follow-up months will have been completed and 95.1% of patients will have completed the two-year follow-up. The results of the analysis are anticipated during the third quarter of 2010 at which point the trial will be complete, with 100% of the randomized patient follow-up available. If the results prove positive for device closure, the Company will be in a position to submit a Pre-Market Approval (PMA) application for its STARFlex(R) device for the stroke and TIA indication to the U.S. Food and Drug Administration (FDA). As previously announced, an independent group of statistical advisors determined that, with a high degree of certainty, a sufficient number of primary outcome events to demonstrate a statistically significant difference in treatment outcomes will have occurred by October 2009. By April 2010, the data is expected to have statistical power to support a primary outcome result and thus it would be scientifically appropriate to begin the analysis at that time. As a result, with FDA and Executive Committee approval, the Company has elected to initiate the data analysis process earlier than the originally planned October 2010 date.